Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Hall, PS, McCabe, C, Stein, RC et al. (1 more author) (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. Journal of the National Cancer Institute, 104 (1). 56 - 66. ISSN 0027-8874

Abstract

Metadata

Authors/Creators:
  • Hall, PS
  • McCabe, C
  • Stein, RC
  • Cameron, D
Copyright, Publisher and Additional Information: © 2012, Oxford University Press. This is an author produced version of a paper published in Journal of the National Cancer Institute. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors (Epidemiology); Cost-Benefit Analysis; Drug Costs; Female; Genetic Testing; Genome, Human; Great Britain; Humans; Lymph Nodes; Lymphatic Metastasis; Markov Chains; Mastectomy, Segmental; Middle Aged; National Health Programs; Neoplasm Staging; Quality-Adjusted Life Years; Receptors, Estrogen; Research Design; Risk Assessment; Tumor Markers, Biological
Dates:
  • Published: 4 January 2012
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 28 Nov 2013 16:26
Last Modified: 29 Mar 2018 16:20
Published Version: http://dx.doi.org/10.1093/jnci/djr484
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/jnci/djr484
Related URLs:

Share / Export

Statistics